News

Pharmaceutical giant Pfizer (NYSE: PFE) recently had to drop its internally developed GLP-1 weight loss drug candidate. The unfortunate outcome is that the company has had to watch rivals Novo

While not the most popular biotech company on the market, Exelixis (NASDAQ: EXEL) has been quietly making a name for itself over the past five years, while delivering strong financial results and

Vertex Pharmaceuticals' (NASDAQ: VRTX) stock price is up, but its Casgevy sales partner, CRISPR Therapeutics (NASDAQ: CRSP), is the real buy for long-term investors.

Shares of Vertex, a biotech

Pfizer (NYSE: PFE) is the name behind one of the world's top-selling products: the coronavirus vaccine. It brought in more than $37 billion at its peak in 2022 and helped the company achieve $100

In today's video, I discuss recent updates affecting Advanced Micro Devices (NASDAQ: AMD) and other AI stocks. To learn more, check out the short video, consider subscribing, and click the special

Investors were snapping up shares of fintech stock Vertex (NASDAQ: VERX) on Thursday. That followed a rather glowing research update from an analyst at a prominent investment bank. With that in its

In today's video, I discuss recent updates affecting Advanced Micro Devices (NASDAQ: AMD) and other AI stocks. To learn more, check out the short video, consider subscribing, and click the special

Most veteran investors can attest that, although they're also often a complete bust, every now and then a biopharma stock dishes out a windfall gain.

That's what the analyst community seems to

It's been a disappointing past few months for shareholders in Advanced Micro Devices (NASDAQ: AMD). After soaring in early October on news that the company will be supplying processing chips for

Palantir Technologies (NASDAQ: PLTR) has become one of the most popular stocks in the market. Like many such stocks, Palantir has been volatile, rising and falling with prevailing sentiment among

According to an SEC filing dated Feb. 18, Naya Capital Management UK Ltd disclosed a new position in Masimo (NASDAQ:MASI), acquiring nearly 1.6 million shares.

Masimo is a leading provider of

What will the world look like five years from now? How you answer the question should help you determine how you invest now.

I expect that healthcare and energy will remain critical in 2031. That's

ImmunityBio (NASDAQ:IBRX), which develops immunotherapies and vaccines for cancers and infectious diseases, closed Wednesday at $8.54, up 41.86%. The stock jumped after the European Commission

The past 12 months haven't been kind to UnitedHealth Group's (NYSE: UNH) stock, which is down over 41% (as of Feb. 16). There are a few reasons for its struggles, including disappointing earnings

Wednesday's trading session is proving to be a thrilling one for ImmunityBio (NASDAQ: IBRX) shareholders. As of 1:50 p.m. ET today the biopharma stock is up an incredible 33.1%. The reason

It's been a rough start in 2026 for Ark Invest co-founder, CEO, and Chief Investment Officer Cathie Wood. The largest exchange-traded fund at her company is trading 10% lower year to date. The

As an investor, you always have the right to bring your own values into your investing decisions. Some investors avoid companies in certain industries because of their personal concerns. In some

Last year was a difficult one for UnitedHealth Group (NYSE: UNH). The biggest health insurer in the U.S. came up against a number of headwinds -- from an ever-changing healthcare landscape to the

Regardless of whether you are looking at a growth stock or dividend stock, cash flow is key. However, when analyzing the safety and reliability of a dividend, cash flow is a must.

In today's video

Investors have bought into the promise of CRISPR technology for years. The ability to target and edit genes to treat cancer and various genetic conditions is an obvious home run. CRISPR Therapeutics

Things have gone from bad to worse for UnitedHealth Group (NYSE: UNH). Last year, the giant health insurer suspended its guidance due to higher-than-expected medical costs. The company replaced its

Vertex Pharmaceuticals (NASDAQ: VRTX) hasn't made the headlines in recent times like companies involved in high-growth areas such as weight loss drugs or artificial intelligence (AI). But this

On February 17, 2026, Rock Springs Capital Management LP disclosed in an SEC filing that it sold 159,379 shares of Agios Pharmaceuticals (NASDAQ:AGIO) in the fourth quarter, an estimated $5.59

Investors who got in on Nvidia (NASDAQ: NVDA) stock a few years ago have seen their returns multiply. The stock has climbed 700% over the past three years as the artificial intelligence (AI)

On February 17, 2026, Nine Ten Capital Management disclosed selling 342,907 shares of IRadimed (NASDAQ:IRMD), an estimated $29.42 million trade based on quarterly average pricing.

According to a